A pharmacoeconomic evaluation of staging modalities for patients with newly diagnosed and occult recurrent adenocarcinoma of the prostate.
Costs of staging prostate cancer using the Kit for the Preparation of Indium In111 capromab pendetide, a radiolabeled monoclonal antibody directed against prostate-specific membrane antigen, were evaluated using a medical decision model. Subjects were patients with newly diagnosed adenocarcinoma at risk for metastatic disease based on prostate specific antigen screening ≥10 and Gleason score ≥7, and occult recurrent disease. Information for the model was obtained from a meta-analysis of data from published medical literature, clinical trials, databases analysis, and expert opinion provided by an expert panel of five specialists in urology, surgery, radiation oncology, and nuclear medicine. When capromab pendetide, computed tomography, magnetic resonance imaging, and pelvic lymph node dissection were compared in patient with newly diagnosed or occult recurrent disease, capromab pendetide produced cost savings due to its ability to identify soft tissue lesions consistent with prostate cancer and to help establish the extent of disease.